Controlling Health Care Costs Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? Issue Briefs / Oct 05, 2017
Controlling Health Care Costs The Case for Drug-Pricing Reform — The Cost of Inaction blog / May 26, 2021
Controlling Health Care Costs External Reference Pricing: The Drug-Pricing Reform America Needs? Issue Briefs / May 27, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs blog / Aug 18, 2021
Improving Health Care Quality Medicare’s Decision to Cover the Alzheimer’s Drug Aduhelm: What Will It Mean for Patients and the Program? Blog / Jan 19, 2022
Achieving Universal Coverage History in the Balance: The Promise of Build Back Better Blog / Jan 12, 2022
Controlling Health Care Costs Brand-Name Drug Prices: The Key Driver of High Pharmaceutical Spending in the U.S. Publication / Nov 17, 2021
Controlling Health Care Costs Supreme Court Will Determine Whether 340B Hospitals Retain Discounts on Medicare Part B Drugs Blog / Nov 11, 2021
Controlling Health Care Costs Domestic Reference Pricing and Its Potential Role in Medicare Pharmaceutical Price Negotiations Explainer / Oct 26, 2021
Controlling Health Care Costs Skinny Labeling: A Pathway for Timely Generic Drug Competition Blog / Oct 19, 2021
Controlling Health Care Costs Policymakers’ Attention Turns to Drug Patents in the Debate on Prices Blog / Oct 07, 2021
Controlling Health Care Costs The U.S. Can Lower Drug Prices Without Sacrificing Innovation Blog / Oct 01, 2021
Controlling Health Care Costs Medicare Patients Pay More for Drugs Than Older Adults in Other Countries; Congress Has an Opportunity to Move Forward Blog / Sep 30, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid Blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs Blog / Aug 18, 2021
